Affinity Asset Advisors’s enGene Therapeutics ENGN Stock Holding History

Affinity Asset Advisors’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.04M	Sell	600,000 -10,370	-2%	-$42.3K	0.05%	105
2026 Q1	$4.16M	Sell	610,370 -33,000	-5%	-$294K	0.21%	78
2025 Q4	$5.81M	Buy	643,370 +566,370	+736%	+$4.54M	0.33%	60
2025 Q3	$526K	Hold	77,000	–	–	0.05%	89
2025 Q2	$280K	Buy	+77,000	New	+$289K	0.04%	81

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Affinity Asset Advisors's ENGN Position: Q2 2026 in Review

Affinity Asset Advisors reduced its enGene Therapeutics (ENGN) stake by 1.7% in Q2 2026, selling an estimated $42.3K and leaving 600,000 shares worth $1.04M. The position accounts for 0.05% of the portfolio, ranked #105.

Affinity Asset Advisors first reported a position in ENGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $5.81M in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

Affinity Asset Advisors held 600,000 shares of enGene Therapeutics worth $1.04M as of Q2 2026.
Affinity Asset Advisors sold 10,370 enGene Therapeutics shares in Q2 2026, an estimated $42.3K.
enGene Therapeutics made up 0.05% of Affinity Asset Advisors's portfolio in Q2 2026, its #105 holding.
Affinity Asset Advisors first reported a position in enGene Therapeutics in Q2 2025 and has held it in 5 quarters since.
Affinity Asset Advisors's enGene Therapeutics position peaked at $5.81M in Q4 2025.
60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.